1
Current Trend in Osteoporosis Management for Elderly in HK-
Medical Perspective
Dr Dicky T.K. ChoyPhysician
Jockey Club Centre for Osteoporosis Care and Control, CUHK
2
Osteoporosis
• Global public health problem• It is an intermediate outcome for fractures
and is a risk factor for fracture just as HT is for stroke
• ** The majority of fractures, however, occur in patients with low bone mass rather than osteoporosis
3
A systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.
Old Definition of Osteoporosis
Conference Report from the Consensus Development Conference:Am J Med 94: 646-650, 1993 4
Normal bone Osteoporosis
Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength primarily reflects the integration of bone density and bone quality.
Current Definition of Osteoporosis
NIH Consensus Development Panel on Osteoporosis JAMA 285:785-95; 2001
5
Pathophysiology
6
A diagram of a cutting cone with osteoclasts resorbingbone followed by osteoblasts depositing new osteoid,
which subsequently becomes calcified
7
Bone remodeling
• Bone loss occurs when this balance is altered, resulting in greater bone removal than replacement
• This imbalance occurs with menopause and advancing age.
Vertebral FractureVertebral FractureVertebral Fracture
Hip FractureHip FractureHip Fracture
Colles FractureCollesColles FractureFracture
9
Epidemiology
10
3%3%5%5%6%6%13%13%MenMen
16%16%16%16%18%18%40%40%WomenWomen
forearmforearmSpine Spine HipHipAllAll
((Melton, 1992)Melton, 1992)
11
Men(1.8 million)
Asia Asia 51%51%
Hip fracture for men and Hip fracture for men and women in 2050women in 2050
Asia Asia 54%54%
EuropeEurope11%11%Others Others
8%8% Latin Latin AmericaAmerica
6%6%
North North AmericaAmerica
13%13%
Women(4.5 million)
Middle Middle EastEast8%8%
EuropeEurope12%12%Others Others
6%6% Latin Latin AmericaAmerica
12%12%
North North AmericaAmerica
12%12%
Middle Middle EastEast6%6% 12
0
100
200
300
400
500
600
Adj
uste
d R
ates
(100
,000
)
US (White) Hong Kong Singapore Thailand Malaysia
535459 442
269218
Age-adjusted incidence rates in women
13
0
50
100
150
200
Adj
uste
d R
ates
(100
,000
)
US (White) Hong Kong Singapore Thailand Malaysia
187 180164
11488
Age-adjusted incidence rates in men
14
Age specific incidence rates for hip, vertebral, and Age specific incidence rates for hip, vertebral, and distal forearm fractures in men and womendistal forearm fractures in men and women
0
1000
2000
3000
4000Men Women
Inci
denc
e/10
0,00
0 pe
rson
-yr
35-39 ≥85 ≥85
Age group, yr
Hip
Vertebral
Colles’
Hip
Vertebral
Colles’
15
0
500
1000
1500
2000
2500
Per 1
00,0
00
50-59 60-69 70-79 80+Age
1966
1985
1995
Incidence of hip fracture in Hong Kong women
16
0
400
800
1200
Per 1
00,0
00
50-59 60-69 70-79 80+Age
1966
1985
1995
Incidence of hip fracture in Hong Kong men
17
Direct cost for osteoporotic fractures
1.1 billion
2.7 billion
Men
2.9 billionHong Kong (hip fracture)
11.1 billionUSA
Women
18
Mortality and morbidity due to hip fracture is high
• 10-20% excess mortality within 1 year
• Up to 25% remain in long term nursing home care
• Only 40% fully regain their pre fracture level of independence
19
Mortality and morbidity due to vertebral fracture is also high
• Significant complications including back pain, height loss and kyphosis
• Limited activity including bending and reaching
• May result in restrictive lung disease if multiple thoracic fractures
• Lumbar fracture may alter abdominal anatomy
20
Approach to the Diagnosis and Management
21
Comprehensive approach
• Detailed history (clinical risk factors assessment including fall risk assessment )
• Bone mineral density (BMD) assessment• Establish fracture risk using WHO 10-year
estimated fracture probability
22
Risk factors included in the WHO 10-year Fracture Risk Assessment Model
• Age• Gender• Personal history of fracture• Parental history of hip fracture• Low body mass index (BMI)• Use of oral glucocorticoid• Secondary osteoporosis (e.g RA )• Current smoking• Alcohol intake 3 or more drinks/day• Femoral neck BMD
23
Risk Factors for Falls
1. Environmental2. Medical3. Neuromuscular4. Fear of falling
24
Environmental
• Low level lighting• Obstacles in the walking path• Lack of assist devices in bathrooms• Slippery outdoor conditions
25
Medical• Age• Arrthymias• Poor vision• Urgent urinary incontinence• Previous fall• Orthostatic hypotension• Medications ( narcotic analgesics, anticonvulsants,
psychotropics )• Depression• Anxiety and agitation• Vit D def• Malnutrition
26
Neuromuscular
• Poor balance• Weak muscles• Kyphosis• Reduced proprioception
WHO definition of osteoporosisWHO definition of osteoporosis
NormalBelow the mean peak adult
<1SDAt -1.0 and above
BMDT score
OsteopeniaBelow the mean peak adult
1-2.5SDBetween -1 and -2.5
BMDT score
OsteoporosisBelow the mean peak adult
>2.5SDat or below -2.5
BMDT score
28
WHO Definition
• Although these definition are necessary to establish the presence of osteoporosis, they should not be used as sole determinant of treatment decisions
29
Bone Densitometry
• Dual x-ray absorptiometry (DXA)
• Quantitative computed tomography (QCT) –
mainly use in research field
• Quantitative ultrasound
30
Dual x-ray absorptiometry(DXA)
• Measure the BMD of lumbar spine ( L1-L4)
and the hip ( femoral neck and total hip )
• Diagnosis based on T-score ( WHO
definition of osteoporosis )
32
33 34
Quantitative Ultrasound (QUS )
Quantitative Ultrasound (QUS )
• Can only used on peripheral bones e.g heel
• Advantages of small size, relatively quick
and simple measurements, and no radiation
36
Indications for BMD testing( NOF recommendation )
• Women > 65 and men > 70, regardless of clinical risk factors
• Younger postmenopausal women and men age 50-70 about whom you have concern based on their clinical risk factor profile
• Women in the menopausal transition if there is a specific risk factor associated with increased fracture risk such as low body weight, prior low trauma fracture, or high risk medication
37
Indications for BMD testing( NOF recommendation )
• Adults with a condition (e.g RA ) or taking a medication (e.g, steroid >5mg/day for > 3months) associated with low bone mass or bone loss
• Anyone being considered for pharmacologic therapy for osteoporosis
• Anyone being treated for osteoporosis, to monitor treatment effect
38
Management
***Multidisciplinary approach
39
Universial Recommendations
1. Adequate intake of calcium and Vit D2. Regular weight bearing exercise3. Fall prevention4. Avoidance of tobacco use and excessive
alcohol intake
40
Adequate intake of calcium and vitamin D
• Lifelong adequate calcium intake is necessary for the acquisition of peak bone mass and subsequent maintenance of bone health
• NOF recommend 1200mg for women age over 50
41
Adequate intake of calcium and vitamin D
• Vitamin D plays a major role in calcium absorption, bone health, muscle performance, balance, and risk of falling
• NOF recommends an intake of 800 to 1000 IU of vitamin D3 ( cholecalciferol ) per day for adults over age 50
42
Drug Treatment
43
Who Should Be Treated???
44
NOF Guideline
Postmenopausal women and men age 50 and older presenting with the following should be treated :
• A hip or vertebral fracture• Other prior fracture and low bone mass• T score <2.5 at the femoral neck, total hip
or lumbar spine after appropriate evaluation to exclude secondary causes
45
NOF Guideline
• Low bone mass with secondary causes associated with high risk of fracture ( such as steroid use or total immobilization )
• Low bone mass and 10-yr probability of hip fracture >3% or a 10-yr probability of any major osteoporosis related fracture >20% based on the WHO model
46
Antiresorptive agents
Bisphosphonates- Alendronate- Risedronate- Ibandronate ( oral and IV )- Zoledronate (IV)Selective Estrogen Receptor Modulators (SERM)
- RaloxifeneStrontium * ( dual action )CalcitoninHRT
47
Anabolic agent
• PTH 1-34 ( Parathyroid hormone )
48
Bisphosphonate
• Inhibitors of osteoclast activity• Strong affinity for calcium ions and are
rapidly taken up by bone• Long skeletal half life• ??? Long term side effects – over
suppressed bone turnover
49
Alendronate ( Fosamax )
• 70mg oral weekly• New formulation ( fosamax plus ) had
vitamin D3 2800/5600IU• Reduce vertebral fracture by 48% over 3
years in patient w/o prior vertebral fracture• Reduce the incidence of vertebral and non-
vertebral fracture by around 50% in patient with prior vertebral fracture
50
Ibandronate ( Bonviva )
• 150mg oral once a month• 3mg every 3 months by IV injection• Reduces the incidence of vertebral fracture
by about 50% over 3 years
51
Risedronate ( Actonel )
• 35 mg oral weekly• Reduces the incidence of vertebral fracture
by 41-49% and non-vertebral fracture by 36% over 3 years
52
Zoledronate ( Aclasta )
• 5mg by IV infusion over at least 15 minsonce yearly
• Reduces the incidence of vertebral fracture by 70%, hip fracture 41% and non-vertebral fracture by 25% over 3 years
53
Side effects of Bisphosphonates
• Similar for all oral bisphosphonates which include GI problems such as dyspepsia, nausea, pain in the bones, muscles and joints. ( need to be taken on an empty stomach, 1st thing in the morning with plenty of plain water, at least 30-60 minsbefore eating or drinking, remain upright during this interval as well )
54
Side effects of Bisphosphonates
• Osteonecrosis of the jaw have been reported (very rare in osteoporosis cases)- usually seen in oncology cases with high dose IV bisphosphonate
55
Drug Interactions with bisphosphonate
• No clinical significant interactions with most common medications
56
SERM(Selective Estrogen Receptor Modulator)
• Raloxifene ( Evista )• 60mg oral daily• Reduces the risk of vertebral fracture by 55% in
patients with prior fracture, 30% in patients w/o prior fracture over 3 years
• Reduces the risk of breast cancer• Increase risk of DVT• Increase hot flashes
57
Effect of Raloxifene on All Breast Cancer IncidenceMORE Trial - 4 Years
Years since Randomization
Total Cases = 77Arrow denotes annual mammogram (*optional)
Adapted from Cauley J et al. Breast Cancer Res Treatment 65:125-34, 2001
0.0
2.0
1.0
1.5
0.5
% o
f Ran
dom
ized
Pat
ient
s
0 1 2 3 4
RR = 0.38 (95% CI = 0.24-0.58)NNT = 94
62%
*
RLX (pooled)
Placebo
58
Strontium Ranelate ( Protos )
• Both anti-resorptive and anabolic effects• 1 sachet ( 2 g ) daily to be taken at bedtime• Reduces vertebral fracture risk by 41% in 3
years, non-vertebral fracture risk by 16%• Side effects of nausea, diarrhea, headache, skin
irritation• Risk of DVT may be increased
59
Calcitonin
• Salmon calcitonin• Single daily intranasal spray / s.c inj• No big RCT data to look at fracture risk
reduction• May reduce back pain caused by acute
vertebral fracture• S/E of nausea, vomiting, dizziness and
flushing may occur60
HRT ( Hormone Replacement Therapy )
• Reduces the risk of clinical vertebral fracture and hip fracture by 34% and other osteoporotic fracture by 23% over 5 years
• Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli and DVT during the 5 years of treatment
• No longer used as 1st line agent to treat osteoporosis
61
Anabolic agent
• PTH 1-34 ( Forteo )• Daily s.c injection• Reduces the risk of vertebral fracture by 65%
and non-vertebral fracture by 53% in patients with osteoporosis, after an average use of 18 months
62
PTH 1-34 (Forteo)
• Side effects of leg cramps and dizziness• Relatively expensive• Safety and efficacy has not been
demonstrated beyond 2 years of treatment• Common practice to follow PTH treatment
with an anti-resorptive agent
63
Combination therapy??
Not recommended – no good research evidence to show better fracture outcome
64
Remaining issues……
65
• How can we better assess bone strength using non-invasive technologies and thus improve identification of patients at high risk of fracture?
• How effective are different drug treatments in preventing fractures in patients with moderately low bone mass?
• How long should anti-resorptive therapies be continued, and are there long term side effects as yet unknown?
• Are combination therapies useful, and if so, which are the useful drug combinations and when should they be used?
• Can we identify agents that will significantly increase bone mass and return bone structure to normal
66
Summary
67
Osteoporosis
• Global public health problem• Very common condition among elderly
( 1 in 2 for women and 1 in 5 in men )• Fracture can KILL• Can be easily diagnosed and have very
effective drug treatment• Multidisciplinary approach
68